Cargando…

Author’s Reply to: “Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Chinese Healthy Subjects”

Detalles Bibliográficos
Autores principales:	Xie, Ran, Zhang, Yang, Zhao, Nan, Zhou, Shuang, Wang, Xin, Han, Wei, Yu, Yan, Zhao, Xia, Cui, Yimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746673/ https://www.ncbi.nlm.nih.gov/pubmed/31502082 http://dx.doi.org/10.1007/s13318-019-00574-8

Ejemplares similares

Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects
por: Xie, Ran, et al.
Publicado: (2018)

Author reply to comments
por: Bhalla, Ashu Seith, et al.
Publicado: (2015)

AUTHOR REPLY TO EDITORIAL COMMENT
por: Shiff, Benjamin, et al.
Publicado: (2021)

Whole Genome Sequencing Analysis of Bacillus thuringiensis GR007 Reveals Multiple Pesticidal Protein Genes
por: Pacheco, Sabino, et al.
Publicado: (2021)

Reply from Authors to the Editorial Comment
por: Kiss, Bernhard, et al.
Publicado: (2016)

Authors' Reply to Comments from Dr. Guan
por: Inoue, Ken-ichiro, et al.
Publicado: (2009)

Authors’ Reply to Comments on ASHAs’ Perceptions on Depression
por: Mary Kapanee, Aruna Rose, et al.
Publicado: (2018)

Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects
por: Xu, Junyu, et al.
Publicado: (2023)

Authors’ reply
por: Shuang, Han, et al.
Publicado: (2016)

Authors’ reply
por: Shuang, Han, et al.
Publicado: (2016)

Authors’ reply to the comment from Uchida et al.
por: Osawa, Itsuki, et al.
Publicado: (2023)

Authors’ reply to the comment from Glass et al.
por: Kotani, Yuki, et al.
Publicado: (2023)

Author's Reply
por: Jeon, Seong Ran
Publicado: (2015)

Author’s Reply
por: Zhao, Li
Publicado: (2020)

Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects
por: Xie, Ran, et al.
Publicado: (2022)

Author's reply
por: Sharma, Pushpa, et al.
Publicado: (2010)

Commentary: A Comment on Qi et al.—Authors’ Reply
por: Qi, X. Sharon, et al.
Publicado: (2012)

Author reply to comment on photodynamic therapy and polypoidal choroidal vasculopathy
por: Williams, Gwyn Samuel, et al.
Publicado: (2014)

The Author Reply: A Comment on “Quaternary Prevention in Public Health”
por: Bae, Jong-Myon
Publicado: (2016)

Authors’ reply to the comment from Benavides-Zora et al.
por: Kotani, Yuki, et al.
Publicado: (2023)

Authors’ Reply to Ganijee et al.: “Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults”
por: Boettcher, Michael, et al.
Publicado: (2023)

Discovery of Novel GR Ligands toward Druggable GR Antagonist Conformations Identified by MD Simulations and Markov State Model Analysis
por: Hu, Xueping, et al.
Publicado: (2021)

AUTHOR REPLY
por: Zhao, Hanson, et al.
Publicado: (2020)

The PPAR-γ antagonist T007 inhibits RANKL-induced osteoclastogenesis and counteracts OVX-induced bone loss in mice
por: Li, Xiang, et al.
Publicado: (2019)

Assessing the importance of interleukin-6 in COVID-19 – Authors' reply
por: Leisman, Daniel E, et al.
Publicado: (2021)

Author`s Reply
por: Gu, Jun, et al.
Publicado: (2019)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Author`s Reply
por: Yao, Mingyang, et al.
Publicado: (2019)

Authors’ Reply: Comment to Varied phenotype of Homocystinuria: Possible diagnostic error
por: Kaliaperumal, Subashini, et al.
Publicado: (2014)

Author reply to comment on subconjunctival limbus oblique incision for mature cataracts
por: Yang, Jun, et al.
Publicado: (2015)

Author’s reply to ‘Rickettsia retinitis cases in India: a few comments’
por: Kawali, Ankush A., et al.
Publicado: (2016)

Authors’ Reply to Critical Comment on “Vitamin D Level in Alopecia Areata”
por: Bhat, Yasmeen Jabeen, et al.
Publicado: (2018)

Authors' Reply to Comments on the Association between Workplace Environment and Metabolic Syndrome
por: Soo Jeong, Hwee
Publicado: (2019)

GR Dimerization and the Impact of GR Dimerization on GR Protein Stability and Half-Life
por: Louw, Ann
Publicado: (2019)

Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A/AT1001) in healthy male Japanese subjects
por: Ino, Hiroko, et al.
Publicado: (2013)

Reply to the comment
por: Okada, Yohei, et al.
Publicado: (2020)

Authors’ Reply: Comment to course of diabetic retinopathy before and after renal transplantation
por: Roy, Rupak, et al.
Publicado: (2014)

Author reply: comment on the drug utilization pattern in chronic obstructive pulmonary disease
por: Veettil, Sajesh Kalkandi, et al.
Publicado: (2015)

Author’s Reply to Comments on “Pneumothorax Induced by Pulmonary Paragonimiasis: Two Cases Report”
por: Kim, Hyun Jo
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6ddin3gr6rvm8pe905ojn5uctm